Climb Bio to present preliminary Phase 2 PrisMN trial data for budoprutug at ASN Kidney Week 2026
CLYM•Climb Bio said it will present preliminary Phase 2 PrisMN study results for budoprutug in primary membranous nephropathy on Oct. 24 at ASN Kidney Week 2026 in Denver. Phase 1 data for CLYM116 in healthy volunteers are scheduled for Oct. 22-23.
1. Conference presentations
Climb Bio flagged clinical updates for budoprutug and CLYM116 ahead of ASN Kidney Week 2026, scheduled for Oct. 21-25 in Denver. Preliminary Phase 2 results from the PrisMN study of budoprutug in primary membranous nephropathy will be presented Oct. 24 as an early look at safety and efficacy.
2. CLYM116 data
Phase 1 data for CLYM116 in healthy volunteers will be presented Oct. 22-23, supporting its development in IgA nephropathy.
